Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

F 182112

Next Previous
Drug Profile

F 182112

Alternative Names: F-182112

Latest Information Update: 24 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lunan Pharmaceutical Group
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 21 Sep 2026 Phase-I clinical trials in Systemic lupus erythematosus in China (Parenteral) (NCT07829614)
  • 18 Sep 2026 Institute of Hematology & Blood Diseases Hospital plans a phase II trial for Multiple myeloma (Combination therapy, Newly diagnosed, First-line therapy) in October 2026 (IV) (NCT07828522)
  • 11 Sep 2026 Institute of Hematology & Blood Diseases Hospital, China in collaboration with Lunan Pharmaceutical Group plans a phase I trial for Autoimmune haemolytic anaemia (Second line therapy or greater) in China (IV) (NCT07816341)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top